Study has shown that the effects of decitabine in thrombocytopenia patients may be due to enhanced megakaryocyte differentiation and maturation.[9] The decitabine, cytarabine, aclarubicin, and G-CSF (DCAG) regimen (decitabine plus cytarabine, low-dose aclarubicin, and granulocyte colony-stimulating factor priming) achieves a definite clinical efficacy in the treatment of intermediate-high-risk MDS and hypo proliferative or senile AML,[1,5,10] but the main side effect of this regimen is severe, long-term thrombocytopenia after chemotherapy. The gene discussed is CSF3; the disease is myelodysplastic syndrome.